BAX

ANALYST NOTE: BAXTER INTERNATIONAL INC. (BAX) DATE: 2026-06-13 CURRENT PRICE: $19.89

1. Structural Readiness

State: Context-Only Conservative Entry: — (Awaiting confirmed breakout) Current Price: $19.89 Extension: — Breakout Level: — (Not yet fired) ATR Current: 3.7% (Productive / Within historical sweet spot)

Setup Analysis:

2. Thesis Layer

Thesis Status: Tactical / Setup-Led Secular Exposure: None Named

There is no named secular thesis attached to BAX as of this date. The investment case is strictly tactical, driven by the quality of the technical setup (the forming coil) and the immediate fundamental inflection points recorded by management. We do not invent a macro thesis. The conviction must be derived entirely from the structural setup quality and the business fundamentals provided in the evidence block. The name is being judged on its ability to execute a margin inflection and deleveraging cycle, rather than on a broad secular growth narrative.

3. Business Overview

Company: Baxter International Inc. Industry: Healthcare / Medical Devices & Supplies Business Model: Diversified provider of essential healthcare products, serving hospitals, dialysis centers, and home-care patients globally.

Core Operations (as of Q1 2026): Baxter operates through three primary segments, as detailed in the Q1 2026 earnings transcript (2026-04-30) and 2026 filings:

• Medical Products & Therapies: Includes sterile IV solutions, infusion systems, administration sets, and parenteral nutrition therapies (E11).
• Healthcare Systems & Technologies: Includes connected care solutions, smart bed systems, patient monitoring, diagnostic technologies, and advanced surgical equipment (E12).
• Pharmaceuticals: Includes specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding (E13).

Recent Strategic Shifts & Performance:

• Divestiture: On January 31, 2025, Baxter completed the sale of its Kidney Care business to Carlyle for $3.80 billion (E19). This transaction was the primary driver for significant debt reduction.
• Deleveraging: As of December 31, 2025, the company repaid $3.81 billion of legacy indebtedness, primarily using proceeds from the Kidney Care sale (E20). Management is committed to a net leverage target of approximately 3.0x by the end of 2026 (E21).
• Growth Drivers:
• Advanced Surgery: Grew 10% in Q1 2026, with a strong order book (E5).
• Drug Compounding: Net sales increased 30% in Q1 2026, driven by international demand (E14).
• Connectivity Solutions: Sustaining strong order books (E5).
• Headwinds:
• Novum LVP Hold: In July 2025, Baxter temporarily halted distribution and installation of the Novum LVP in the U.S. and Canada due to regulatory uncertainty. Management expects no meaningful sales from this product while the hold is in effect (E9).
• Supply Chain & Costs: Q1 2026 gross margins decreased 5.0 percentage points year-over-year, driven by manufacturing costs, tariffs, product mix, and supply chain disruptions from events like Hurricane Helene (E15, E16).
• Sales Growth: Q1 reported sales grew 3% YoY, but organic sales declined 1% (E1). Full-year guidance remains flat to 1% reported growth (E2).

4. Archetype and Conviction

Archetype: Margin Inflector / Deep Value Recovery Rationale: BAX fits the Margin Inflector archetype. The company has executed a major balance sheet restructuring (selling Kidney Care to deleverage) and is now in the execution phase of a cost-structure optimization program. Management explicitly states expectations to "fully roll through absorption headwinds" in the second half of the year and realize benefits from right-sizing actions (E8).

Fundamental Context:

• Guidance: Management expects full-year adjusted operating margins to range between 13% and 14% (E3).
• Earnings: Full-year adjusted EPS is guided to $1.85–$2.05 (E4).
• Costs: The company estimates a full-year net impact of $80 million from special items, representing a $40 million year-over-year headwind (E7).
• R&D: R&D expenditures were $518 million in 2025, down from $590 million in 2024, indicating a focus on cost discipline (E22).

Conviction Stack:

• Thesis Strength: Low (Tactical only; no secular tailwinds).
• Evidence Quality: High (Clear management guidance on margins, deleveraging, and specific segment growth).
• Structural Quality: Moderate (Forming coil indicates a base, but volatility and regulatory overhangs exist).
• Setup Readiness: Partial (Forming state; requires breakout confirmation).
• Rerating Potential: Moderate. The rerating potential is tied to the successful execution of the margin expansion (13-14% target) and the completion of the deleveraging cycle (3.0x leverage target). The market is currently pricing in the headwinds (supply chain, Novum hold); a successful "roll-through" of these headwinds in H2 2026 could drive a re-rating.

Valuation Context: Forward consensus EPS for FY1 is $1.92 and FY2 is $1.99 (E37). At a current price of $19.89, the stock trades at approximately 10.3x FY1 consensus. This valuation reflects the "deep value" aspect of the turnaround story, pricing in the execution risk of the margin inflection.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Margin Expansion: Q2 or Q3 results showing gross margins stabilizing or expanding as the "absorption headwinds" roll through (E8).
• Deleveraging Progress: Confirmation that net leverage is on track to hit the 3.0x target by year-end 2026 (E21).
• Novum LVP Resolution: Regulatory clarity allowing the resumption of Novum LVP sales.

What Would Invalidate the Case:

• Fundamental Deterioration: A miss on the full-year adjusted operating margin guidance (13-14%) or a widening of the organic sales decline beyond the current 1% (E2).
• Regulatory Escalation: Extension of the Novum LVP hold beyond expectations, causing a material revenue shortfall.
• Supply Chain Disruption: Further significant weather or geopolitical events impacting results beyond the Q1 2026 baseline (E16).

Evidence Gaps:

• Q2 2026 Data: The evidence block ends with Q1 2026 results (April 30, 2026). There is no data for Q2 2026 performance to confirm if the "roll-through" of headwinds is actually occurring.
• Debt Metrics: While the target is 3.0x, the exact current leverage ratio as of June 13, 2026, is not explicitly stated in the provided text (only the target and past repayment actions).

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Management guidance for 13-14% adjusted operating margins and $1.85-$2.05 EPS; successful deleveraging with $3.81B debt repayment; strong growth in Advanced Surgery (10%) and Drug Compounding (30%). Key risks: Novum LVP sales hold causing revenue loss; gross margin compression from tariffs and supply chain disruptions; technical setup remains in "forming" state without confirmed breakout. Sizing hint: Position size should be conservative until the breakout fires; the 3.7% ATR allows for standard volatility sizing but the setup is incomplete. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation) and for margin inflection to materialize.